Mitobridge Inc, an Astellas Company, 1030 Massachusetts Ave, Cambridge, MA 02138, USA.
Bioorg Med Chem Lett. 2019 Jun 1;29(11):1270-1277. doi: 10.1016/j.bmcl.2019.03.041. Epub 2019 Mar 29.
Mitochondrial dysfunction is a causative and/or exacerbating feature of many pathologies. We discuss below approaches to modulate mitochondrial dysfunction that involve (1) increasing their energetic efficiency by targeting gene expression regulators such as PPAR or AMPK, (2) using antioxidant compounds to reduce the toxic reactive oxygen species mitochondria produce under stress, or (3) modulating aspects on the innate mitochondrial quality control system. The latter comprise linked processes of biogenesis, dynamic morphological changes, and elimination of defective mitochondria by mitophagy. We discuss representative compounds in all three classes.
线粒体功能障碍是许多病理的病因和/或加重因素。我们在下面讨论了调节线粒体功能障碍的方法,包括:(1)通过靶向基因表达调节剂如过氧化物酶体增殖物激活受体(PPAR)或 AMP 激活的蛋白激酶(AMPK)来提高其能量效率;(2)使用抗氧化化合物来减少线粒体在应激下产生的有毒活性氧物质;(3)调节先天的线粒体质量控制系统的各个方面。后者包括生物发生、动态形态变化和通过线粒体自噬消除有缺陷的线粒体的相关过程。我们讨论了所有这三个类别的代表性化合物。